Core Insights - The investor reaction to Phreesia's third-quarter performance was overly negative despite the company showing significant improvements in revenue and profitability [1][8] Financial Performance - Phreesia reported a 13% year-over-year increase in revenue, exceeding $120 million, driven by a 7% growth in the average number of healthcare services clients to 4,520 [2][4] - The company achieved a net profit of nearly $4.3 million ($0.07 per share), a turnaround from a loss of $14.4 million in the same quarter last year, with both revenue and profit figures surpassing analyst expectations [4][5] Revenue Streams - All three revenue streams—subscription and related services, network solutions, and payment processing—grew at low double-digit rates of 12%, 14%, and 11% respectively during the quarter [5] Guidance and Market Reaction - Phreesia tightened its full-year 2026 revenue guidance to $479 million to $481 million, slightly below analyst expectations of nearly $486 million [6] - The company's forecast for non-GAAP EBITDA was raised to $99 million to $101 million, up from a previous range of $89 million to $92 million [7] - Despite the stock's significant drop of over 23% following the earnings release, the negative sentiment appears exaggerated, primarily due to the revenue guidance miss [1][8]

Core Insights - Phreesia reported revenue of $120.33 million for the quarter ended October 2025, reflecting a year-over-year increase of 12.7% and a slight revenue surprise of +0.17% over the Zacks Consensus Estimate of $120.13 million [1] - The company's EPS for the quarter was $0.10, a significant improvement from -$0.25 in the same quarter last year, although it did not deliver an EPS surprise against the consensus estimate of $0 [1] Financial Performance Metrics - Average healthcare services clients were reported at 4,520, slightly below the estimated 4,530 [4] - Patient payment volume reached $1.18 billion, exceeding the estimated $1.16 billion [4] - Payment facilitator volume percentage was 85%, surpassing the average estimate of 81.3% [4] - Revenue from subscription and related services was $55.48 million, slightly above the estimated $55.44 million, with a year-over-year change of +12.4% [4] - Revenue from network solutions was $37.43 million, close to the estimated $37.46 million, showing a year-over-year increase of +14.4% [4] - Revenue from payment processing fees was $27.42 million, exceeding the estimated $27.25 million, representing an 11% increase compared to the previous year [4] Stock Performance - Over the past month, Phreesia's shares have returned -7.9%, contrasting with the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Wall Street analysts expect Phreesia (PHR) to report quarterly earnings of $0.00 per share, reflecting a year-over-year increase of 100% [1] - Revenue projections for Phreesia are set at $120.13 million, which represents a 12.5% increase from the same quarter last year [1] - There has been a 50% upward revision in the consensus EPS estimate over the last 30 days, indicating a significant reassessment by analysts [1] Revenue Estimates - Analysts estimate 'Revenue - Subscription and related services' to be $55.44 million, marking a 12.3% increase from the previous year [4] - 'Revenue - Network solutions' is projected to reach $37.46 million, indicating a 14.5% year-over-year change [4] - 'Revenue - Payment processing fees' is expected to be $27.25 million, reflecting a 10.3% increase compared to the prior year [5] Client and Volume Metrics - The average number of healthcare services clients is anticipated to be 4,530, up from 4,237 in the same quarter last year [5] - The consensus estimate for 'Patient payment volume' is $1.16 billion, compared to $1.08 billion from the previous year [5] - Analysts project a 'Payment facilitator volume percentage' of 81.3%, slightly up from 81.0% year-over-year [6] Stock Performance - Over the past month, Phreesia shares have declined by 10.6%, while the Zacks S&P 500 composite has seen a minor decrease of 0.1% [6] - Phreesia holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the overall market in the near future [6]

Core Insights - Phreesia reported revenue of $117.26 million for the quarter ended July 2025, reflecting a year-over-year increase of 14.8% and a surprise of +0.7% over the Zacks Consensus Estimate of $116.45 million [1] - The company's EPS was $0.01, a significant improvement from -$0.31 in the same quarter last year, resulting in an EPS surprise of +114.29% compared to the consensus estimate of -$0.07 [1] Financial Performance Metrics - Average healthcare services clients were reported at 4,467, slightly below the three-analyst average estimate of 4,475 [4] - Patient payment volume reached $1.25 billion, exceeding the average estimate of $1.18 billion from three analysts [4] - Payment facilitator volume percentage was 82%, closely aligning with the average estimate of 82.2% based on two analysts [4] - Revenue from subscription and related services was $53.7 million, below the average estimate of $55.27 million from six analysts, but still showing a year-over-year increase of +10.5% [4] - Revenue from network solutions was $35.16 million, surpassing the six-analyst average estimate of $33.25 million, with a year-over-year change of +24.7% [4] - Revenue from payment processing fees was $28.39 million, slightly above the six-analyst average estimate of $27.9 million, reflecting a year-over-year increase of +12.2% [4] Stock Performance - Phreesia's shares have returned +12.3% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]